News & Updates

The advent of new lipid-lowering agents, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has led to guideline updates on management of chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). In addition to potent LDL-cholesterol (LDL-C) reduction, alirocumab may mitigate atherosclerotic cardiovascular disease (ASCVD) risk by inducing plaque stabilization and exerting protective vascular effects.

The phase IIb Advance-HTN trial shows the blood pressure (BP)-lowering effect of lorundrostat in patients with uncontrolled and treatment-resistant hypertension (HTN).